REGENERON PHARMACEUTICALS, INC. Loss Contingency, Damages Sought, Value
REGENERON PHARMACEUTICALS, INC. (REGN) reported Loss Contingency, Damages Sought, Value of EUR 10.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Notes › Loss Contingency
us-gaap:LossContingencyDamagesSoughtValue · last filed 2018-11-06
- REGENERON PHARMACEUTICALS, INC. loss contingency, damages sought, value for the quarter ending 2018-03-31 was 10.00M EUR, a 0.00% change year-over-year.
- REGENERON PHARMACEUTICALS, INC. loss contingency, damages sought, value for the quarter ending 2017-12-31 was 0.00 EUR.
- REGENERON PHARMACEUTICALS, INC. loss contingency, damages sought, value for the quarter ending 2017-09-30 was 0.00 EUR.
- REGENERON PHARMACEUTICALS, INC. loss contingency, damages sought, value for the quarter ending 2017-06-30 was 0.00 EUR.
- REGENERON PHARMACEUTICALS, INC. loss contingency, damages sought, value for fiscal 2017 was 10.00M EUR, a 0.00% change from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. loss contingency, damages sought, value for fiscal 2016 was 10.00M EUR.
| Period end | Loss Contingency, Damages Sought, Value | Loss Contingency, Damages Sought, Value 3 month | Loss Contingency, Damages Sought, Value 6 month | Loss Contingency, Damages Sought, Value 9 month | Loss Contingency, Damages Sought, Value 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | 10.00M EUR 10-Q · filed 2018-05-03 | 10.00M EUR derived: sum of 2 quarters · filed 2018-05-03 | 10.00M EUR derived: sum of 3 quarters · filed 2018-05-03 | 10.00M EUR derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-12-31 | 0.00 EUR derived: 10-K 12 month − 10-K 9 month · filed 2018-02-08 | 0.00 EUR derived: sum of 2 quarters · filed 2018-02-08 | 0.00 EUR derived: sum of 3 quarters · filed 2018-02-08 | 10.00M EUR 10-K · filed 2018-02-08 | |
| 2017-09-30 | 0.00 EUR derived: 10-K 9 month − 10-Q 6 month · filed 2018-02-08 | 0.00 EUR derived: sum of 2 quarters · filed 2018-02-08 | 10.00M EUR 10-K · filed 2018-02-08 | 10.00M EUR derived: sum of 4 quarters · filed 2018-02-08 | |
| 2017-06-30 | 0.00 EUR derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | 10.00M EUR 10-Q · filed 2017-08-03 | 10.00M EUR derived: sum of 3 quarters · filed 2017-08-03 | ||
| 2017-03-31 | 10.00M EUR 10-Q · filed 2017-05-04 | 10.00M EUR derived: sum of 2 quarters · filed 2017-05-04 | |||
| 2016-12-31 | 0.00 EUR derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | 10.00M EUR 10-K · filed 2017-02-09 | |||
| 2016-09-30 | 10.00M EUR 10-Q · filed 2016-11-04 | ||||
| 2016-09-26 | 10.00M EUR 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |